tiprankstipranks
Trending News
More News >
Cel-Sci Corp. (CVM)
:CVM

Cel-Sci (CVM) Price & Analysis

Compare
757 Followers

CVM Stock Chart & Stats


Financials

Ownership Overview

1.80%3.25%1.78%90.29%
1.78% Other Institutional Investors
90.29% Public Companies and Individual Investors

CVM FAQ

What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $1.98 and its highest was $66.57 in the past 12 months.
    What is Cel-Sci Corp.’s market cap?
    Cel-Sci Corp.’s market cap is $12.43M.
      When is Cel-Sci Corp.’s upcoming earnings report date?
      Cel-Sci Corp.’s upcoming earnings report date is Aug 18, 2025 which is in 67 days.
        How were Cel-Sci Corp.’s earnings last quarter?
        Cel-Sci Corp. released its earnings results on May 15, 2025. The company reported -$2.4 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.4.
          Is Cel-Sci Corp. overvalued?
          According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Cel-Sci Corp. pay dividends?
            Cel-Sci Corp. does not currently pay dividends.
            What is Cel-Sci Corp.’s EPS estimate?
            Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Cel-Sci Corp. have?
            Cel-Sci Corp. has 5,135,021 shares outstanding.
              What happened to Cel-Sci Corp.’s price movement after its last earnings report?
              Cel-Sci Corp. reported an EPS of -$2.4 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.144%.
                Which hedge fund is a major shareholder of Cel-Sci Corp.?
                Currently, no hedge funds are holding shares in CVM

                Cel-Sci Stock Smart Score

                Company Description

                Cel-Sci Corp.

                CEL-SCI Corporation is a biotechnology company focused on the research and development of immunotherapy products for the treatment of cancer and infectious diseases. The company operates in the biotechnology sector and its core product is Multikine, an investigational immunotherapy aimed at harnessing the body's immune system to improve the treatment of various cancers, particularly head and neck cancer.
                Similar Stocks
                Company
                Price & Change
                Follow
                NanoViricides
                Enlivex
                Pulmatrix
                Ovid Therapeutics
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis